Literature DB >> 2667346

De novo membranous glomerulonephropathy in renal allografts: a report of ten cases and review of the literature.

L Truong1, J Gelfand, V D'Agati, J Tomaszewski, G Appel, M Hardy, C L Pirani.   

Abstract

De novo posttransplantation membranous glomerulonephropathy (MGN) is the most common form of de novo glomerulopathy in renal allografts. The clinical and pathological features of ten patients with de novo MGN were studied and the related literature was reviewed to assess the clinical features, morphologic characteristics, and natural course of this disease. De novo MGN may occur in both living related and cadaveric allografts at any time after transplantation. It presents clinically either as asymptomatic proteinuria or the nephrotic syndrome, a feature of poor prognostic implication. Morphologically, de novo MGN in most instances has distinct differences from idiopathic MGN in native kidneys and is accompanied by varying features of rejection. About 50% of grafts which develop de novo MGN eventually fail. This rather poor outcome may not represent the natural history of de novo MGN per se but rather the consequences of associated chronic rejection. Evidence is presented that many of the cases of so-called de novo MGN may be a complication of transplant glomerulopathy rather than being caused by mechanisms totally independent from rejection.

Entities:  

Mesh:

Year:  1989        PMID: 2667346     DOI: 10.1016/s0272-6386(89)80189-1

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  8 in total

1.  A rare cause of proteinuria after kidney transplantation: Answers.

Authors:  Nilüfer Göknar; Seha Saygılı; Nur Canpolat; Yasemin Özlük; Işın Kılıçaslan; Lale Sever; Salim Çalışkan
Journal:  Pediatr Nephrol       Date:  2019-04-30       Impact factor: 3.714

Review 2.  Glomerular disease of transplanted kidneys.

Authors:  U Frei
Journal:  Clin Investig       Date:  1993-10

3.  Beneficial effect of rituximab in the treatment of recurrent idiopathic membranous nephropathy after kidney transplantation.

Authors:  Ben Sprangers; George Ian Lefkowitz; Scott D Cohen; Michael Barry Stokes; Antony Valeri; Gerald B Appel; Cheryl L Kunis
Journal:  Clin J Am Soc Nephrol       Date:  2010-02-25       Impact factor: 8.237

4.  Partial therapeutic response to Rituximab for the treatment of chronic alloantibody mediated rejection of kidney allografts.

Authors:  R Neal Smith; Fahim Malik; Nelson Goes; Alton B Farris; Emmanuel Zorn; Susan Saidman; Nina Tolkoff-Rubin; Sonika Puri; Waichi Wong
Journal:  Transpl Immunol       Date:  2012-08-30       Impact factor: 1.708

Review 5.  Recurrent primary disease and de novo nephritis following renal transplantation.

Authors:  J S Cameron
Journal:  Pediatr Nephrol       Date:  1991-07       Impact factor: 3.714

Review 6.  De novo glomerular diseases after renal transplantation.

Authors:  Claudio Ponticelli; Gabriella Moroni; Richard J Glassock
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-03       Impact factor: 8.237

Review 7.  De novo glomerular diseases after renal transplantation: How is it different from recurrent glomerular diseases?

Authors:  Fedaey Abbas; Mohsen El Kossi; Jon Kim Jin; Ajay Sharma; Ahmed Halawa
Journal:  World J Transplant       Date:  2017-12-24

8.  Long-term outcomes of patients with end-stage kidney disease due to membranous nephropathy: A cohort study using the Australia and New Zealand Dialysis and Transplant Registry.

Authors:  Wen-Ling Yang; Bhadran Bose; Lei Zhang; Megan Mcstea; Yeoungjee Cho; Magid Fahim; Carmel M Hawley; Elaine M Pascoe; David W Johnson
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.